PREVNAR 20
Pneumococcal 20-valent conjugate (Pneu-C-20)
0.5 mL · suspension · intramuscular · 6 weeks and older
Pneumococcal
Pneumococcal
PREVNAR 20 · VAXNEUVANCE · CAPVAXIVE
Infant series, and one dose for adults 65 and older or at higher risk. Every product below is a Health Canada authorized vaccine; every schedule comes from the Canadian Immunization Guide.
- Products
- 3
- Dose schedules
- 4
- Guidance checked
- 2026-09-27
Authorized products
Brand names and DINs (Drug Identification Numbers) as Health Canada's Drug Product Database lists them. The product monograph is the manufacturer's full prescribing information approved by Health Canada.
VAXNEUVANCE
Pneumococcal 15-valent conjugate (Pneu-C-15)
0.5 mL · suspension · intramuscular · 6 weeks and older
CAPVAXIVE
Pneumococcal 21-valent conjugate (Pneu-C-21)
0.5 mL · solution · intramuscular · 18 years and older
Before and after vaccination
- Bring your immunization record so earlier doses can be checked.
- Discuss a serious reaction to a previous vaccine, relevant health conditions, medicines and allergies before receiving a dose.
- After vaccination, stay where you can be observed for at least 15 minutes and report feeling faint or signs of an allergic reaction right away.
- Keep the vaccine name, date and dose in your immunization record.
Based on the Canadian Immunization Guide's administration practices and acute reactions guidance.
Pregnancy & breastfeeding
Pregnancy
Recommended for people at high risk of pneumococcal disease.
Breastfeeding
Recommended for people at high risk of pneumococcal disease.
Source: Immunization in pregnancy and breastfeeding: Canadian Immunization Guide — Chapter updated August 2026. Live vaccines are generally contraindicated in pregnancy; routinely recommended vaccines can be given while breastfeeding unless the chapter says otherwise.
How many doses
The schedules the Canadian Immunization Guide describes for this vaccine. Which one applies depends on age, health and product — use the dose planner to see the dates for your situation.
Pneumococcal conjugate — healthy infant, three doses (2 + 1)
3 dosesTwo doses at 2 and 4 months plus a booster at 12 months.
Routine schedule for healthy infants in provinces using a 2 + 1 series, including Ontario: doses at 2 and 4 months, then a booster at 12 months of age. Minimum 8 weeks between doses; the booster is not given before 12 months of age. Infants with risk factors need the four-dose (3 + 1) schedule.
ProductsPREVNAR 20VAXNEUVANCE
Pneumococcal conjugate — higher-risk infant, four doses (3 + 1)
4 dosesThree doses at 2, 4 and 6 months plus a booster at 12 to 15 months.
For infants with immunocompromising conditions, chronic heart, lung, kidney or liver disease, cochlear implants, CSF leak, sickle cell disease or asplenia, and premature infants: doses at 2, 4 and 6 months followed by a booster at 12 to 15 months. Minimum 8 weeks between doses; the booster is not given before 12 months of age.
ProductsPREVNAR 20VAXNEUVANCE
Pneumococcal conjugate — adults 65 and older, one dose
1 doseOne dose of Pneu-C-20 or Pneu-C-21 for all adults 65 years and older.
All adults 65 years and older: one dose of Pneu-C-20 or Pneu-C-21 regardless of earlier pneumococcal vaccination, given at least 1 year after any previous Pneu-C-13, Pneu-C-15 or Pneu-P-23 dose (8 weeks in some circumstances). No further doses are currently recommended.
ProductsPREVNAR 20CAPVAXIVE
Pneumococcal conjugate — adults 18 to 64 with risk factors, one dose
1 doseOne dose of Pneu-C-20 or Pneu-C-21 for adults 18 to 64 with a condition that raises the risk of pneumococcal disease.
Adults 18 to 64 with immunocompromising conditions (HIV, asplenia, transplant, cancer, immunosuppressive therapy) or other risk factors for invasive pneumococcal disease (chronic heart, lung, kidney or liver disease, diabetes, alcohol use disorder, cochlear implant, CSF leak): one dose at least 8 weeks after any earlier pneumococcal vaccine. Stem-cell transplant recipients need a three-dose series plus booster instead.
ProductsPREVNAR 20CAPVAXIVE
References and product information
- Pneumococcal vaccines: Canadian Immunization Guide — Chapter revised May 2024 · partial update July 2026
- Vaccine administration practices: Canadian Immunization Guide
- Anaphylaxis and other acute reactions: Canadian Immunization Guide
- Health Canada Drug Product Database — product records and monographs
- Pharmasist vaccine reference: PREVNAR 20
- Pharmasist vaccine reference: VAXNEUVANCE
- Pharmasist vaccine reference: CAPVAXIVE
Clinical rules reviewed on 2026-09-27. General information from public Canadian guidance; a personal assessment is needed for treatment decisions. Care365 does not decide whether a vaccine is publicly funded in Ontario.